EuroMRD Publications
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines
van der Velden VHJ, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D, Eckert C, Fronkova E, Hancock J, Kotrova M, Kraemer R, Montonen M, Pfeifer H, Pott C, Raff T, Trautmann H, Cavé H, Schäfer BW, van Dongen JJM, Trka J, Brüggemann M; EuroMRD Consortium.
Reference: Leukemia. 2024, May 14
Link: https://pubmed.ncbi.nlm.nih.gov/38744919/
The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category
Kotrova M, Fronkova E, Svaton M, Drandi D, Schön F, Hoogeveen P, Hancock J, Skotnicova A, Schilhabel A, Eckert C, Clappier E, Cazzaniga G, Schäfer BW, van Dongen JJM, Ritgen M, Pott C, van der Velden VHJ, Trka J, Brüggemann M.
Reference: Leukemia. 2024, May 17
Link: https://www.nature.com/articles/s41375-024-02265-z
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on MRD-based protocol
Svaton M, Skotnicova A, Reznickova L, Rennerova A, Valova T, Kotrova M, van der Velden VHJ, Brüggemann M, Darzentas N, Langerak AW, Zuna J, Stary J, Trka J, Fronkova E
Reference: Blood. 2022 Oct 14;doi: 10.1182/blood.2022017003
Link: https://pubmed.ncbi.nlm.nih.gov/36240445/
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
Kotrová M, Koopmann J, Trautmann H, Alakel N, Beck J, Nachtkamp K, Steffen B, Raffel S, Viardot A, Wethmar K, Darzentas N, Baldus CD, Gökbuget N, Brüggemann M
Reference: Blood Adv. 2022;6:3006-3010
Link: https://pubmed.ncbi.nlm.nih.gov/35026836/
One-Step Next-Generation Sequencing of Immunoglobulin and T-Cell Receptor Gene Recombinations for MRD Marker Identification in Acute Lymphoblastic Leukemia
Villarese P, Abdo C, Bertrand M, Thonier F, Giraud M, Salson M, Macintyre E
Reference: Methods Mol Biol. 2022;2453:43-59
Link: https://link.springer.com/protocol/10.1007/978-1-0716-2115-8_3
Immunoglobulin/T-Cell Receptor Gene Rearrangement Analysis Using RNA-Seq
van der Velden VHJ, Bastian L, Brüggemann M, Hartmann AM, Darzentas N
Reference: Methods Mol Biol. 2022;2453:61-77
Link: https://link.springer.com/protocol/10.1007/978-1-0716-2115-8_4
Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR
Starza ID, Eckert C, Drandi D, Cazzaniga G; EuroMRD Consortium
Reference: Methods Mol Biol. 2022;2453:79-89
Link: https://link.springer.com/protocol/10.1007/978-1-0716-2115-8_5
Quality Control for IG /TR Marker Identification and MRD Analysis
Fronkova E, Svaton M, Trka J
Reference: Methods Mol Biol. 2022;2453:91-99
Link: https://link.springer.com/protocol/10.1007/978-1-0716-2115-8_6
cfDNA-Based NGS IG Analysis in Lymphoma
Pott C, Kotrova M, Darzentas N, Brüggemann M, Khouja M; EuroClonality-NGS Working Group
Reference: Methods Mol Biol. 2022;2453:101-117
Link: https://link.springer.com/protocol/10.1007/978-1-0716-2115-8_7
Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas
Genuardi E, Alessandria B, Civita AM, Ferrero S
Reference: Methods Mol Biol. 2022;2453:119-132
Link: https://link.springer.com/protocol/10.1007/978-1-0716-2115-8_8
PCR Technology to Identify Minimal Residual Disease
Cazzaniga G, Songia S, Biondi A; EuroMRD Working Group
Reference: Methods Mol Biol 2021;2185:77-94
Link: https://pubmed.ncbi.nlm.nih.gov/33165844/
Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
Van der Velden VHJ, Brüggemann M, Cazzaniga G, Scheijen B, Tops B, Trka J, Pal K, Hänzelmann S, Fazio G, Songia S, Langerak AW, Darzentas N; EuroMRD; EuroClonality-NGS Working Group
Reference: Leukemia 2021;35:924-928
Link: https://pubmed.ncbi.nlm.nih.gov/33608635/
Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders
Drandi D, Ferrero S, Ladetto M
Reference: Methods Mol Biol. 2018;1768:229-256
Link: https://pubmed.ncbi.nlm.nih.gov/29717447/
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
Pfeifer H, Cazzaniga G, van der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, Akiki S, Avigad S, Bendit I, Borg K, Cavé H, Elia L, Reshmi SC, Gerrard G, Hayette S, Hermanson M, Juh A, Jurcek T, Chillón MC, Homburg C, Martinelli G, Kairisto V, Lange T, Lion T, Mueller MC, Pane F, Rai L, Damm-Welk C, Sacha T, Schnittger S, Touloumenidou T, Valerhaugen H, Vandenberghe P, Zuna J, Serve H, Herrmann E, Markovic S, van Dongen JJM, Ottmann OG
Reference: Leukemia 2019;33:1910-1922
Link: https://pubmed.ncbi.nlm.nih.gov/30858550/
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Starza ID, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, Ferrero S, Macintyre E
Reference: Hemasphere. 2020;4:e347
Link: https://pubmed.ncbi.nlm.nih.gov/32309784/
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
van Dongen JJM, van der Velden VH, Brüggemann M, Orfao A
Reference: Blood. 2015;125:3996-4009
Link: https://pubmed.ncbi.nlm.nih.gov/25999452/
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
Van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJM; European Study Group on MRD detection in ALL (ESG-MRD-ALL)
Reference: Leukemia 2007;21:604-11
Link: https://pubmed.ncbi.nlm.nih.gov/17287850/